New study tracks Real-World use of eczema drug abrocitinib
NCT ID NCT06353087
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study follows 200 people aged 12 and older with moderate-to-severe eczema who are starting a new prescription of abrocitinib. Researchers will track how much their skin improves over 12 months using standard eczema severity scores. The goal is to see how well the drug works in real-world settings, outside of controlled clinical trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
abrocitinib
What this could lead to
If successful, this study could confirm that abrocitinib works well in real-world settings for people with moderate-to-severe eczema, helping doctors make better treatment decisions.
What could go wrong
This is an observational study, not a controlled trial, so results may be less reliable. It only follows people for 12 months, and long-term effects or rare side effects may not be captured.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DERMATITIS, ATOPIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chang Gung Hospital Linkou
NOT_YET_RECRUITINGTaoyuan, 333, Taiwan
-
Chang Gung Memorial Hospital at Kaohsiung
RECRUITINGKaohsiung City, 83301, Taiwan
-
Kaohsiung Medical University Hospital
NOT_YET_RECRUITINGKaohsiung City, 807377, Taiwan
-
MacKay Memorial Hospital
NOT_YET_RECRUITINGTaipei, 10449, Taiwan
-
NTUH
RECRUITINGTaipei, 100, Taiwan
-
Taipei Medical University - Shuang Ho Hospital
NOT_YET_RECRUITINGNew Taipei City, 23561, Taiwan
-
Taipei Veterans General Hospital
NOT_YET_RECRUITINGTaipei, 11217, Taiwan
-
Tri-Service General Hospital
NOT_YET_RECRUITINGTaipei, 11490, R.O.C., Taiwan